Physician profile
Eric Hunke
NPI 1194196097
$11,183.31
in general payments reported to CMS, 2019-2025
42 companies · $1,184 in 2025
The $1,184 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,969 · 2022: $2,612 · 2023: $2,143 · 2024: $2,275 · 2025: $1,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,601.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,731.83 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,487.88 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $1,135.62 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,032.47 | 2021-2024 | Breztri, Farxiga, Airsupra |
| Esperion Therapeutics, INC. | $789.64 | 2021-2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $421.03 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $386.72 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $332.86 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $323.49 | 2021 | |
| Glaxosmithkline, LLC. | $270.31 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $253.83 | 2021-2025 | |
| Abbott Laboratories | $245.56 | 2021-2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $235.40 | 2023-2025 | Gemtesa |
| Amarin Pharma, INC. | $207.25 | 2021-2022 | |
| Astellas Pharma US INC | $204.29 | 2022-2024 | Veozah, Myrbetriq |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Hunke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.